Z. Zivkovic (Belgrade, Yugoslavia), R. Buhl (Mainz, Germany)
The risk of hospitalization, near fatal and fatal asthma in relation to the perception of dyspnoea
R. Magadle, N. Berar-Yanay, P. Weiner (Hadera, Israel)
|  |
High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor
K. Zech, M. David, M. Seiberling, C. Weimar, T. Bethke, W. Wurst (Konstanz, Freiburg)
| |
Menopausal symptoms decrease health-related quality of life of women with asthma
T. Kuzniar, K. Kasibowska-Kuzniar, J. Patkowski, R. Jankowska (Wroclaw, Poland)
| |
Evidence of a distinct phenotype of adult onset asthma characterized by an airway neutrophilia and poor response to inhaled corticosteroids
R. H. Green, G. Woltmann, C. E. Brightling, A. J. Wardlaw, I. D. Pavord (Leicester, United Kingdom)
| |
Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma
R. Buhl, J. P. H. M. Creemers, V. Vondra, N. A. Martelli (Mainz, Eindhoven, Germany; Prague, Czech Republic; Buenos Aires, Argentina)
| |
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma
R. Buhl, J. P. H. M. Creemers, V. Vondra, N. A. Martelli (Mainz, Germany; Eindhoven, The Netherlands; Prague, Czech Republic; Buenos Aires, Argentina)
| |
Budesonide/formoterol in a single inhaler improves asthma control more effectively than a higher dose of fluticasone
E. D. Bateman, T. A. Bantje, M. Joao Gomes, M. Toumbis, R. Huber, A. Eliraz (Cape Town, South Africa; Breda, The Netherlands; Lisbon, Portugal; Athens, Greece; Munich, Germany; Rehovot, Israel)
| |
Prolonged activity where it matters - the reversible esterfication of budesonide improves its topical anti-inflammatory efficacy and selectivity in the airways
A. Miller-Larsson, S. Edsbäcker, R. Brattsand (Lund, Sweden)
| |